GLP-1 receptor agonists have nearly two decades of clinical use and millions of patient-years of safety data, making them well-studied therapies despite patient perceptions of being 'new.'
Millions of Patient-YearsGLP-1 receptor agonists have accumulated millions of patient-years of real-world safety data since their clinical introduction, far from being 'experimental'
What the researchers found
GLP-1 receptor agonists are far from experimental novelties — GLP-1 was first discovered in the 1980s, and these drugs have accumulated nearly two decades of clinical experience with millions of patient-years of safety data. Newer agents like semaglutide and tirzepatide use structural modifications that prolong the hormone's action without fundamentally changing its mechanism. Safety data consistently show that side effects are predominantly mild, transient gastrointestinal issues, with no confirmed evidence supporting feared risks such as cancer.
Why it matters
Patient reluctance to start GLP-1 medications due to perceived 'newness' is a real barrier to treatment, even as these drugs show significant benefits for diabetes, obesity, and cardiovascular health. By providing clinicians with concrete talking points grounded in the actual research timeline and safety record, this guide could help more patients access effective peptide-based therapies.
How the study worked
The authors wrote a clinical commentary synthesizing the history of GLP-1 research, comparing native GLP-1 to modern receptor agonists, and reviewing existing safety data. They developed a practical counseling checklist and sample patient-centered language to help clinicians facilitate informed decision-making conversations.
What this study cannot tell us
This is a clinical commentary rather than a systematic review or original research study. It does not present new safety data but synthesizes existing information. The counseling strategies provided, while practical, have not been formally tested for effectiveness in improving patient adherence or reducing hesitancy.
How to read the evidence
This is a clinical commentary and counseling guide, not original research. It synthesizes well-established safety data and historical context rather than generating new evidence, placing it lower on the evidence hierarchy but high in practical clinical utility.
When this study was published
Published in 2026, this commentary reflects the latest safety data and clinical experience with GLP-1 receptor agonists, including newer agents like tirzepatide.
The bigger picture
As GLP-1 receptor agonists become one of the most widely discussed drug classes in medicine, public perception hasn't kept pace with the science. This commentary bridges that gap by reframing the conversation from 'new and scary' to 'well-researched and proven,' which is critical as semaglutide and tirzepatide expand into new indications beyond diabetes and obesity.
Questions still open
- How effective are structured counseling approaches at reducing patient hesitancy toward GLP-1 receptor agonists?
- As GLP-1 RAs expand to new indications, will longer-term safety data continue to support the current favorable profile?
- Do patients who receive targeted counseling about GLP-1 history and safety show better medication adherence?
Common questions
Are GLP-1 drugs really new?
Do GLP-1 receptor agonists cause cancer?
Read the original research
Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.
American journal of preventive cardiology, 26, 101418
Citation
Shah, Priyansh P; Bhattacharya, Romit. (2026). Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.. American journal of preventive cardiology, 26, 101418. https://doi.org/10.1016/j.ajpc.2026.101418